KR100908796B1 - 아세트산아닐리드 유도체의 α형 또는 β형 결정 - Google Patents

아세트산아닐리드 유도체의 α형 또는 β형 결정 Download PDF

Info

Publication number
KR100908796B1
KR100908796B1 KR1020047006428A KR20047006428A KR100908796B1 KR 100908796 B1 KR100908796 B1 KR 100908796B1 KR 1020047006428 A KR1020047006428 A KR 1020047006428A KR 20047006428 A KR20047006428 A KR 20047006428A KR 100908796 B1 KR100908796 B1 KR 100908796B1
Authority
KR
South Korea
Prior art keywords
crystals
ethyl
amino
hydroxy
aminothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020047006428A
Other languages
English (en)
Korean (ko)
Other versions
KR20050040837A (ko
KR100908796B9 (ko
Inventor
가와조에소이치로
사카모토겐이치로
아와무라유지
마루야마다쓰야
스즈키다카유키
온다겐이치
다카스도시유키
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19148268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100908796(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20050040837A publication Critical patent/KR20050040837A/ko
Application granted granted Critical
Publication of KR100908796B1 publication Critical patent/KR100908796B1/ko
Anticipated expiration legal-status Critical
Publication of KR100908796B9 publication Critical patent/KR100908796B9/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
KR1020047006428A 2001-10-30 2002-10-29 아세트산아닐리드 유도체의 α형 또는 β형 결정 Ceased KR100908796B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2001-00332914 2001-10-30
JP2001332914 2001-10-30
PCT/JP2002/011217 WO2003037881A1 (en) 2001-10-30 2002-10-29 α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE

Publications (3)

Publication Number Publication Date
KR20050040837A KR20050040837A (ko) 2005-05-03
KR100908796B1 true KR100908796B1 (ko) 2009-07-22
KR100908796B9 KR100908796B9 (ko) 2024-07-17

Family

ID=19148268

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047006428A Ceased KR100908796B1 (ko) 2001-10-30 2002-10-29 아세트산아닐리드 유도체의 α형 또는 β형 결정

Country Status (17)

Country Link
US (2) US7342117B2 (enExample)
EP (3) EP1932838A3 (enExample)
JP (1) JP3800220B2 (enExample)
KR (1) KR100908796B1 (enExample)
CN (1) CN1243740C (enExample)
AU (1) AU2002344419C1 (enExample)
BR (1) BRPI0213570B8 (enExample)
CA (1) CA2464068C (enExample)
ES (1) ES2404071T3 (enExample)
HU (1) HU230481B1 (enExample)
MX (1) MXPA04003936A (enExample)
NO (1) NO326965B1 (enExample)
PL (1) PL218982B1 (enExample)
RU (1) RU2303033C2 (enExample)
TW (1) TW200300020A (enExample)
WO (1) WO2003037881A1 (enExample)
ZA (1) ZA200403044B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TR201802207T4 (tr) * 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
JP5782438B2 (ja) * 2010-06-16 2015-09-24 武田薬品工業株式会社 アミド化合物の結晶
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (enExample) * 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
JPWO2013147134A1 (ja) 2012-03-30 2015-12-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
CN103387500A (zh) * 2012-05-11 2013-11-13 上海医药工业研究院 一种米拉贝隆及其中间体的制备方法
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103641792B (zh) * 2013-12-27 2015-07-22 国药集团国瑞药业有限公司 一种米拉贝隆有关物质或其盐、其制备方法和用途
CN104876889B (zh) * 2014-02-27 2017-02-22 人福医药集团股份公司 化合物的合成方法
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
CN103896872A (zh) * 2014-04-29 2014-07-02 黑龙江大学 米拉贝隆的合成方法
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
WO2016020440A1 (en) * 2014-08-06 2016-02-11 Interquim, S.A. Method for the synthesis of mirabegron and its derivatives
WO2016024284A2 (en) 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN105481705A (zh) * 2014-08-23 2016-04-13 南京海纳医药科技有限公司 (r)-2-[[2-(4-氨基苯基)乙基]氨基]-1-苯乙醇的制备及应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
EP3197449B1 (en) * 2014-09-26 2018-11-21 Universita' Degli Studi di Bari Selective agonists of beta-adrenergic type 3 receptors (bar3) for the treatment of nephrogenic diabetes insipidus
CA2962664A1 (en) * 2014-10-01 2016-04-07 Apotex Inc. Solid forms of mirabegron
US9981927B2 (en) 2015-02-02 2018-05-29 Lupin Limited Process for preparation of polymorphic form of Mirabegron
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
FR3043555B1 (fr) 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) Mirabegron pour le traitement de maladies retiniennes
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
CN105801438A (zh) * 2016-04-12 2016-07-27 济南大学 一种米拉贝隆中间体的合成方法
CN107963976A (zh) * 2016-10-20 2018-04-27 中国动物疫病预防控制中心 一种苯乙醇胺类化合物中间体的制备方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
CN108658797A (zh) * 2018-06-19 2018-10-16 安徽德信佳生物医药有限公司 一种米拉贝隆中间体(r)-2-(4-硝基苯乙基氨基)-1-苯基乙醇盐酸盐的合成
CN108947853A (zh) * 2018-06-29 2018-12-07 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成米拉贝隆中间体的方法
KR101928987B1 (ko) * 2018-08-28 2018-12-13 (주) 성운파마코피아 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
NZ774649A (en) 2018-12-05 2025-07-25 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
CN110590699B (zh) * 2019-09-29 2022-11-15 广东先强药业有限公司 一种米拉贝隆的精制方法
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
CN114539182B (zh) * 2020-11-24 2024-08-09 威智医药股份有限公司 转晶溶剂及其应用和米拉贝隆α晶型的制备方法
CN114539084B (zh) * 2020-11-24 2024-04-02 威智医药股份有限公司 米拉贝隆及其中间体的制备方法
CN112574137A (zh) * 2021-01-19 2021-03-30 南京美瑞制药有限公司 一种α晶型米拉贝隆的制备方法
KR20240116208A (ko) 2023-01-20 2024-07-29 이니스트에스티 주식회사 결정형의 미라베그론 신규염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466952A1 (en) * 1989-04-18 1992-01-22 Yoshitomi Pharmaceutical Industries, Ltd. Thiadiazine compound with a novel crystalline form
JP2000212168A (ja) * 1999-01-22 2000-08-02 Yamanouchi Pharmaceut Co Ltd ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶
EP1028111A1 (en) * 1997-10-17 2000-08-16 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1921577B2 (de) * 1969-04-28 1972-04-06 Nixdorf Computer Ag, 4790 Paderborn Trommelartige vorrichtung zn buchungs- und schreibautomaten mit greifeinrichtung zum erfassen und einziehen von kontokarten o dgl
BR9807506A (pt) * 1997-01-23 2000-03-21 Yamanouchi Pharma Co Ltd Derivados de amida e composições medicinais dos mesmos
JP3901832B2 (ja) 1998-03-13 2007-04-04 大日本インキ化学工業株式会社 キノリノン誘導体製剤、及びその製造法
CA2349663C (en) * 1999-09-10 2006-10-31 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466952A1 (en) * 1989-04-18 1992-01-22 Yoshitomi Pharmaceutical Industries, Ltd. Thiadiazine compound with a novel crystalline form
EP1028111A1 (en) * 1997-10-17 2000-08-16 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof
JP2000212168A (ja) * 1999-01-22 2000-08-02 Yamanouchi Pharmaceut Co Ltd ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법

Also Published As

Publication number Publication date
TW200300020A (en) 2003-05-01
EP2298752A1 (en) 2011-03-23
HUP0401665A1 (hu) 2004-11-29
KR20050040837A (ko) 2005-05-03
RU2004116313A (ru) 2005-03-27
AU2002344419C1 (en) 2024-02-01
MXPA04003936A (es) 2004-06-18
RU2303033C2 (ru) 2007-07-20
JPWO2003037881A1 (ja) 2005-02-17
EP1932838A2 (en) 2008-06-18
US7982049B2 (en) 2011-07-19
EP2298752B1 (en) 2013-03-27
ZA200403044B (en) 2005-06-29
AU2002344419B2 (en) 2007-12-13
EP1440969A4 (en) 2005-01-19
US7342117B2 (en) 2008-03-11
EP1440969A1 (en) 2004-07-28
CA2464068A1 (en) 2003-05-08
EP1932838A3 (en) 2008-07-30
BRPI0213570B1 (pt) 2018-02-27
CA2464068C (en) 2007-10-16
CN1243740C (zh) 2006-03-01
HUP0401665A3 (en) 2008-05-28
US20050004190A1 (en) 2005-01-06
TWI322805B (enExample) 2010-04-01
HU230481B1 (hu) 2016-07-28
NO20042227L (no) 2004-05-28
BR0213570A (pt) 2004-10-26
BRPI0213570B8 (pt) 2021-05-25
KR100908796B9 (ko) 2024-07-17
PL369874A1 (en) 2005-05-02
US20080214633A1 (en) 2008-09-04
PL218982B1 (pl) 2015-02-27
CN1575287A (zh) 2005-02-02
WO2003037881A1 (en) 2003-05-08
NO326965B1 (no) 2009-03-23
ES2404071T3 (es) 2013-05-23
JP3800220B2 (ja) 2006-07-26

Similar Documents

Publication Publication Date Title
KR100908796B1 (ko) 아세트산아닐리드 유도체의 α형 또는 β형 결정
KR20100043210A (ko) 신규한 결정 및 5-（｛［2-아미노-3-（4-카르바모일-2,6-다이메틸-페닐）-프로피오닐］-［1-（4-페닐-1ｈ-이미다졸-2-일）-에틸］-아미노｝-메틸）-2-메톡시-벤조산의 제조 방법
KR101153606B1 (ko) 아타자나비르 비술페이트 및 신규 형태의 제조 방법
WO2008099944A1 (en) Crystalline forms of thiazolidinedione derivative and its manufacturing method
IL101358A (en) Crystalline tiagabine hydrochloride monohydrate its preparation and pharmaceutical composition containing it
WO2020051014A1 (en) Processes for the preparation of tenapanor and intermediates thereof
WO2024095127A1 (en) Solid state forms of tivozanib and process for preparation thereof
KR100536750B1 (ko) 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
EP2021339B1 (en) Rosiglitazone hydrochloride hemihydrate
CN101684088B (zh) 氰甲基吡咯衍生物、其制备方法和用途
GB2100261A (en) Aminophenylalkylamine derivatives, a process for their preparation and their use as pharmaceuticals
WO2022060945A1 (en) Solid state forms of gefapixant and process for preparation thereof
JPH0225417A (ja) 抗潰瘍剤
JP2010180169A (ja) アミド化合物の結晶
KR20080003600A (ko) 피롤로피리미디논 유도체의 말리에이트 염 및 이의제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 3, Claim Number : 2, 3, 4, Period Limitation Text : 566, Comment Text : 29

St.27 status event code: A-4-4-G10-G18-tex-PA0101

FPAY Annual fee payment

Payment date: 20140626

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 3, Claim Number : 2, 3, 4, Period Limitation Text : 566, Comment Text : 29

St.27 status event code: A-4-4-G10-G20-tex-PE0702

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

PJ0205 Invalidation trial for registration of extension of term of patent right

St.27 status event code: A-5-5-V10-V11-apl-PJ0205

J204 Request for invalidation trial [patent]
PJ0205 Invalidation trial for registration of extension of term of patent right

St.27 status event code: A-5-5-V10-V11-apl-PJ0205

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150410

Effective date: 20160504

PJ1301 Trial decision

Decision date: 20160504

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002377

Decision date: 20160504

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002373

Decision date: 20160504

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002371

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150410

Effective date: 20160602

PJ1301 Trial decision

Decision date: 20160602

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002661

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

FPAY Annual fee payment

Payment date: 20160616

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

FPAY Annual fee payment

Payment date: 20170616

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PJ1202 Withdrawal of action (patent court)

St.27 status event code: A-5-5-V10-V13-crt-PJ1202

J122 Written withdrawal of action (patent court)
PJ1202 Withdrawal of action (patent court)

St.27 status event code: A-5-5-V10-V13-crt-PJ1202

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

FPAY Annual fee payment

Payment date: 20190617

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J301 Trial decision

Free format text: TRIAL NUMBER: 2015100002397; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100001648; TRIAL DECISION FOR INVALIDATION REQUESTED 20150328

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100002487; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100002023; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100002386; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100002029; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100002388; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100002391; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100001530; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20191126

Free format text: TRIAL NUMBER: 2015100001889; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20191126

PJ1301 Trial decision

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002023

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001530

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150328

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001648

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001889

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002575

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002029

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002386

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002388

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002391

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002397

Decision date: 20191126

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0908796

Appeal request date: 20150410

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002487

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ2002 Appeal before the supreme court

St.27 status event code: A-5-5-V10-V12-crt-PJ2002

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 14

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 15

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC2102 Extinguishment

St.27 status event code: N-4-6-H10-H13-oth-PC2102

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2020200001311; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20200117

Effective date: 20210122

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2021300010343; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20210303

Effective date: 20240328

PJ1302 Judgment (patent court)

Decision date: 20210122

Decision identifier: 2020200001311

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 20151530 (0908796), 20151648 (0908796), 20152029 (0908796), 20152397 (0908796), 20152487 (0908796)

Appeal request date: 20200117

Appellate body name: Patent Court

St.27 status event code: A-5-5-V10-V15-crt-PJ1302

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2021300010343; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20210303

Effective date: 20240328

PJ1303 Judgment (supreme court)

Decision date: 20240328

Decision authority category: Court of appeal

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2020 1311 (0908796)

Appeal request date: 20210303

Appellate body name: Supreme Court

Decision identifier: 2021300010343

Decision text: .(1. . 2. 1 11 908796 2, 8 10 12 . 3. 908796 3, 4 6 .) : 3(3, 4 6), : 5(2, 8 10, 12)

St.27 status event code: A-5-5-V10-V15-crt-PJ1303

PG1701 Publication of correction

Patent document republication publication date: 20240717

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1009087960000

Gazette reference publication date: 20090722

St.27 status event code: A-5-5-P10-P19-oth-PG1701